


FIG. 1




FIG. 2




FIG. 3




FIG. 4



FIG. 5A



FIG. 5B



FIG. 5C



FIG. 5D



FIG. 5E



FIG. 5F




FIG. 5G



FIG. 5H



FIG. 5I



FIG. 5J




FIG. 5K



FIG. 5L



FIG. 5M



FIG. 5N



FIG. 5O



FIG. 5P



FIG. 5Q




FIG. 5R




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 6E



FIG. 6F



FIG. 6G



FIG. 6H



FIG. 6I




FIG. 6J



FIG. 6K




FIG. 6L



FIG. 6M




FIG. 6N




FIG. 6O




FIG. 7




FIG. 8




FIG. 9




FIG. 9A




FIG. 10




FIG. 10A



Plot of Mean Change From Pain Baseline Score
Change in Pain VAS (+/- SD)
2
1
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
Visit
BL [1]
Day 2
Day 3
Day 7
Day 10
Day 14
Day 21
Day 28
Number of Subjects
LiRIS 200mg
9
9
8
9
8
8
7
8

FIG. 11



Plot of Mean Change From Urinary Urgency Baseline Score
Change in Urgency VAS (+/- SD)
1
0
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
-11
Visit
BL [1]
Day 2
Day 3
Day 7
Day 10
Day 14
Day 21
Day 28
Number of Subjects
LIRIS 200mg
8
8
7
8
7
7
6
7

FIG. 12



Plot of Mean Change From Baseline Number of Voids During 24 Hours
Change in Urgency VAS (+/- SD)
0
-2
-4
-6
-8
-10
-12
-14
-16
-18
-20
Visit:
BL [1]
Day 2
Day 3
Day 7
Day 10
Day 14
Day 21
Day 28
Number of Subjects
LiRIS 200mg
9
9
8
9
8
8
8
8

FIG. 13



Plot of Mean Change From Baseline Nocturia During 24 Hours
Change in Number of Voids (+/- SD)
1
0
-1
-2
-3
-4
-5
-6
-7
-8
Visit
BL [1]
Day 2
Day 3
Day 7
Day 10
Day 14
Day 21
Day 28
Number of Subjects
LiRIS 200mg
9
9
8
9
8
8
8
8

FIG. 14



Plot of Mean Baseline Change In Interstitial Cystitis Symptom Index (ICSI)
Change in ICSI (+/- SD)
2
0
-2
-4
-6
-8
-10
-12
-14
-16
-18
Visit:
BL [1]
Day 2
Day 3
Day 7
Day 10
Day 14
Day 21
Day 28
Number of Subjects
LIRIS 200mg
9
9
8
8
9
8
8
8
8

FIG. 15



Plot of Proportion of "ICSI Responders" By Time Point
100
90
80
70
60
50
40
30
20
10
0
Visit:
Day 2
Day 3
Day 7
Day 10
Day 14
Day 21
Day 28
Number of Subjects
LIRIS 200mg
3/9
6/8
6/9
5/8
6/8
5/8
4/8

FIG. 16



Plot of Mean Baseline Change In Interstitial Cystitis Problem Index (ICPI)
Change in ICSI (+/- SD)
4
2
0
-2
-4
-6
-8
-10
-12
-14
-16
-18
Visit
BL [1]
Day 2
Day 3
Day 7
Day 10
Day 14
Day 21
Day 28
Number of Subjects
LIRIS 200mg
9
9
8
9
8
8
8
8

FIG. 17



Plot of Proporation of "ICPI Responders" By Time Point
Proportion of ICPI Responders
100
90
80
70
60
50
40
30
20
10
0
Visit:
Day 2
Day 3
Day 7
Day 10
Day 14
Day 21
Day 28
Number of Subjects
LIRIS 200mg
3/9
6/8
6/9
5/8
6/8
5/8
4/8

FIG. 18



Plot of Proportion of GRA "Responders" By Time Point
Proportion of Global Response Assessment Responders
100
90
80
70
60
50
40
30
20
10
0
Visit:
Day 2
Day 3
Day 7
Day 10
Day 14
Day 21
Day 28
Number of Subjects
LIRIS 200mg
3/9
4/8
5/9
6/8
7/8
4/8
5/8

FIG. 19



Cumulative Lidocaine Release Rate From 200 mg Device
Cumulative Lidocaine Released (mg PBE)
140
120
100
80
60
40
20
0
0
2
4
6
8
10
12
14
16
Average (n=3)
Elasped Time (days)

FIG. 20



Lidocaine Release Rate From 200 mg Device
Lidocaine Released (mg PBE/day)
30
25
20
15
10
5
0
0
2
4
6
8
10
12
14
16
Average (n=3)
Elasped Time (days)

FIG. 21



Cumulative Lidocaine Release Rate From 650 mg Device
Cumulative Lidocaine Released (mg PBE)
400
350
300
250
200
150
100
50
0
0
2
4
6
8
10
12
14
Elasped Time (days)
Average (n=3)

FIG. 22



Lidocaine Release Rate From 650 mg Device
Lidocaine Released (mg PBE/day)
70
60
50
40
30
20
10
0
0
2
4
6
8
10
12
14
Elasped Time (days)
Average (n=3)

FIG. 23